Photodynamic therapy in highly myopic eyes with choroidal neovascularization: 5 years of follow-up

Retina. 2011 Jun;31(6):1089-94. doi: 10.1097/IAE.0b013e3181ff9546.


Purpose: To evaluate the long-term safety and efficacy of photodynamic therapy in the treatment of choroidal neovascularization associated with pathologic myopia.

Methods: Five-year retrospective study of 43 consecutive eyes of 36 patients with juxtafoveal or subfoveal choroidal neovascularization and pathologic myopia treated with photodynamic therapy.

Results: Mean best-corrected visual acuity changed from 20/125 +1 letter (0.78 logarithm of the minimum angle of resolution) at baseline to 20/100 (0.70 logarithm of the minimum angle of resolution) at 5 years (P = 0.122). Final best-corrected visual acuity improved in 53.5% of the eyes, remained stable in 11.6%, and decreased in 34.9%. A visual acuity gain of ≥3 lines occurred in 32.6% of the eyes, and a visual acuity decrease of ≥3 lines was registered in 20.9% of the cases at 5 years. Only patient's age and initial visual acuity showed to have a significant predictive value for the final visual acuity outcome (P = 0.024 and P = 0.002, respectively).

Conclusion: Photodynamic therapy with verteporfin may increase the chance of stabilizing and improving vision in patients with choroidal neovascularization from pathologic myopia at 5 years. Better results were found in younger patients (<55 years).

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / physiopathology
  • Follow-Up Studies
  • Humans
  • Middle Aged
  • Myopia, Degenerative / complications*
  • Myopia, Degenerative / physiopathology
  • Photochemotherapy*
  • Photosensitizing Agents / therapeutic use
  • Porphyrins / therapeutic use
  • Retreatment
  • Retrospective Studies
  • Treatment Outcome
  • Verteporfin
  • Visual Acuity / physiology
  • Young Adult


  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin